The prognostic significance of survivin expression in patients with HNSCC: a systematic review and meta-analysis

Background Survivin has been recently identified as a promising novel therapeutic target and prognostic marker in different types of cancer. Here we conducted a comprehensive meta-analysis to better clarify they the precise prognostic and diagnostic value of survivin in head and neck squamous cell carcinoma (HNSCC). Methods Database of PubMed (Medline), Embase, and Web of Science were systematically searched for related published literature up to September 2020. Pooled hazards ratios (HR) and related 95% confidence intervals (CI) were used to estimate the association of survivin expression and survival outcomes in HNSCC patients. Results Twenty eight studies with 4891 patients were finally included in this meta-analysis, the pooled analysis indicated that the survivin expression was significantly correlated with poorer overall survival (OS) (HR, 2.02; 95% CI, 1.65–2.47, P < 0.001), and poorer disease-free survival (DFS)/ disease-specific survival (DSS) (HR = 2.03, 95%CI: 1.64–2.52, P < 0.001; HR = 1.92, 95%CI: 1.41–2.60, P < 0.001, receptively). Similar results were observed in subgroup analysis stratified by different cancer types, such as laryngeal squamous cell carcinoma (LSCC) (HR = 1.35, 95%CI: 1.05–1.74, P < 0.001), oral squamous cell carcinomas (OSCC) (HR = 2.45, 95%CI: 1.89–3.17, P < 0.001), nasopharyngeal carcinoma (NPC) (HR = 2.53, 95%CI: 1.76–3.62, P < 0.001) and HNSCC (HR = 1.52, 95%CI: 1.25–1.86, P < 0.001). Furthermore, ethnicity-stratified analysis indicated that survivin was significantly associated with poorer OS among both Asian and Non- Asian HNSCC patients (HR = 2.16, 95%CI: 1.76–2.66; HR = 1.56, 95%CI: 1.33–1.82, respectively). Conclusions Our results suggested that survivin is predictors of worse prognosis in HNSCC patients. Hence, survivin is a potential therapeutic target for HNSCC. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-08170-3.


Introduction
Head and neck squamous cell carcinoma (HNSCC) is ranking as the sixth most prevalent cancer worldwide [1], they develop from the squamous mucosa of the upper aerodigestive tract, including nasal cavity, nasopharynx, larynx, hypopharynx, oropharynx and so on. Squamous cell carcinoma (SCC) accounts for up to 90% of malignant tumor in the head and neck region. The group of malignancies have similar pathogenesis, staging system, therapeutic strategy, and prognosis despite they arise from different sites of head and neck region, hence, it is rational to classify them into one category, HNSCC [2]. There are several risk factors associated with HNSC C, such as environmental exposures, tobacco use, alcohol consumption and so on [3]. Although the diagnosis and multimodality treatments improved quickly, the 5year survival rate still remains very low due to the complex anatomy of head and neck region [4]. Therefore, it is necessary to identify more reliable new prognostic biomarkers and therapeutic targets.
Survivin, an important member of the 'inhibitor of apoptosis' (IAP) family, is encoded by baculoviral inverted repeats (BIR) C5 gene [5]. The expression is minimal in normal tissues, however, strong survivin expression is largely observed in numerous cancers [6]. Survivin is an anti-apoptotic factor and regulate intrinsic and extrinsic apoptotic pathways by interacting with many factors. It also plays key roles in cellular stress response by interfering with autophagy. Different proteins of the autophagic machinery, such as Beclin 1, chemokine ligand 2 and light chain 3 interact with survivin [7,8]. In addition, survivin expression is associate with the process of angiogenesis, it overcomes G2/M phase of the cell cycle and causes mitotic progression in most adults' cancers [9].
Although numerous researches have revealed the association between survivin and the prognosis of HNSCC, the results still remain controversial due to the variance in the sample size, study design, test approach and cutoff value. Therefore, it is essential to clarify the diagnostic and prognostic value of survivin in HNSCC based on the findings from the independently small sample size publications. Here, we searched PubMed (Medline), Embase, and Web of Science databases for relevant publications and undertaken a comprehensive meta-analysis to systematically assess the diagnostic and prognostic role of survivin in HNSCC.

Search strategy
We searched for articles published between 2000 and 2020. Electronic searches for relevant retrieve studies were performed throughout databases, including PubMed (Medline), Web of Science and EMBASE databases in accordance with Dickersin et al. in September 2020 [10]. The retrieval strategy included: (survivin) and (prognosis OR outcome OR mortality OR survival OR progression OR recurrence) and (head and neck or laryngeal or tonsil or oropharyngeal or oral or oropharynx or nasopharyngeal) and (squamous cell cancer or carcinoma). Furthermore, the reference lists of retrieved articles for additional articles were also manually searched.
If several studies reported the same patient populations, we enrolled the most complete one to avoid duplication.

Selection criteria
This meta-analysis was limited to studies about the association between HNSCC and survivin. The inclusion criteria of the meta-analysis were as follows: (1) all patients should be diagnosed with HNSCC; (2) survivin was evaluated in both samples of the HNSCC and normal controls; (3) studies revealed the association between survivin and survival of HNSCC; (4) sufficient statistical analysis was required, including hazard ratios (HR) and their related 95% confidence interval (95% CI)) for survival outcomes, if not we could calculate them by p values and Kaplan-Meier curves [11] (5) the language of publications was limited to English. The exclusion criteria were: (1) studies without sufficient data for metaanalysis; (2) abstracts, case reports, reviews, letters, expert opinions, etc.; (3) studies about cell lines, in vivo/ vitro studies, and human xenografts. If the same cohort was reported by several studies, the most recent one was included in our study.

Data extraction
We inspected the duplicates, and removed the repeated papers first. Then, we perused the titles and abstracts of the papers carefully. At last full articles were selected to include the appropriate studies. Two researchers independently evaluated the literature against the inclusion and exclusion criteria (LQ Zhou and Y Hu). Any discrepancy in assessments was resolved by consulting an adjudicating with a third researcher (HJ Xiao). The researchers of the studies were contacted by e-mail to request data or additional information for meta-analytic calculations. The eligible studies for this meta-analysis were reviewed by two reviewers (LQ Zhou and Y Hu) independently. The Newcastle-Ottawa Quality Assessment Scale (NOS) was included to assess the methodological qualities of each publication, a star system (range from 0 to 9) was adopted to evaluate a including publications in three domains, comparability of study groups (2 stars), selection of participants (4 stars) and the outcome measurement (3 stars). A study with NOS ≥ 6 was seemed as a high-quality study [12,13]. Reporting recommendations for tumor marker prognostic studies (REMARK), which were developed to address widespread deficiencies in the reporting of such studies, was also applied to evaluate study quality in the present meta-analysis [14]. The REMARK checklist consists of 20 items to report for published tumor marker prognostic studies. They provide a comprehensive overview to educate on good reporting and also provide a valuable reference for the many issues to consider when designing, conducting, and analyzing tumor marker studies and, with minimal adjustment, in prognostic studies in medicine in general.

Statistical analysis
The HR and the related 95% CI of survival outcomes were obtained directly from the primary publications or estimated by p values and other published data following Parmer's methods [15]. Statistical heterogeneity among the studies was evaluated using the χ 2 -based Q test and the I 2 statistics [16]. The fixed-effects model was employed for analysis without obvious statistical heterogeneity between studies (P > 0.10, I 2 < 50%). Otherwise, the random-effects model was applied. Moreover, we performed subgroup analysis to explore the potential source of heterogeneity. Sensitivity analysis was conducted to investigate the influence of each individual study on the overall pooled results. We used the Begg's and Egger's tests to assess the potential publication bias. We conducted all statistical analyses by STATA statistical software version 15.0 (StataCorp Lp).

Selection and characteristics of included studies
A total of 778 potential records were initially identified by searching the electronic databases (Fig. 1). Following exclusion of the duplicates (n = 431), reviews, abstracts and letters (n = 25) and the studies of irrelevant topics (n = 244), 78 studies were remained for further assessment by reading their full-text articles. A total of 50 studies did not provide specific data regarding HNSCC or survivin and therefore were excluded. Finally, a total 4891 HNSCC patients in 28 studies with publication years ranging from 2002 to 2019 were enrolled in the present meta-analysis.
The characteristics of the eligible studies were summarized in Table 1. The participants were from China, Tunisia, Turkey, Germany, Italy, Australia, Canada, South Korea, Sweden and Slovenia. Immunohistochemistry (IHC) and/or reverse-transcription polymerase chain reaction (RT-PCR) were used to analysis the survivin protein and/or mRNA expression in the including studies. The characters of antibodies in different studies are summarized in Table S1. They have different clones, dilutions, sources and positive signals. Different PCR instruments were also used in different studies. Our metaanalysis including eight studies for laryngeal squamous cell carcinoma (LSCC), ten studies for oral squamous cell carcinomas (OSCC), five studies for head and neck squamous cell carcinoma (HNSCC) and five studies for nasopharyngeal carcinoma (NPC). Fifteen publications included > 100 patients and 13 publications enrolled < 100 patients, twenty one studies including a total of 3036 patients reported overall survival (OS), nine studies including a total of 925 patients reported disease-free survival (DFS) and three studies including a total of 1485 patients reported disease-specific survival (DSS). The HR and 95% CI were directly reported in fifteen studies and were estimated in thirteen studies in the original literature. All of the publications' NOS scores were above 6 and the REMARK scores were between 11 and 15.

Association between survivin and survival outcomes of HNSCC patients
A total of twenty one studies in the present analysis examined the association between survivin and the OS of in HNSCC patients. The heterogeneity among the publications in our study was significant for Q test (P < 0.1). Hence, the random-effects model was adopted and subgroup analysis was used to seek for the potential causes of heterogeneity. The results of these studies indicated expression of survivin were associated with poorer OS (HR, 2.02; 95% CI, 1.65-2.47, P < 0.001). Medium heterogeneity was noted (I 2 = 50.3%, P heterogeneity = 0.005) (Fig. 2). Nine studies examined the association between    survivin and the DFS and three studies examined the association between survivin and the DSS in HNSCC patients. Figure 3 summarized HR for DFS (HR = 2.03, 95%CI: 1.64-2.52) and DSS (HR = 1.92, 95%CI: 1.41-2.60), and there was no significant heterogeneity noted between survivin expression and DFS (I 2 = 0.0%, P heterogeneity = 0.875), low heterogeneity was noted between survivin expression and DSS (I 2 = 40.2%, P heterogeneity = 0.188).
Sensitivity analysis. The sensitivity analysis was applied to detect the effects of each single study on the overall effect. The analysis did not detect a study that could alter significantly the combined results (Fig. 6). The results of the sensitivity analysis indicated that the pooled effect size of the meta-analysis results was stable and reliable.

Publication bias
The publication bias was assessed by the Begg's funnel plots and the Egger's test in the present study. The results indicated the publication bias existed among the studies (p = 0.018). Therefore, "trim and fill" analysis was further utilized, and the pooled HR of 1.569 (95% CI, 1.276-1.930) remained statistically significant (Fig. 7),   . These findings confirmed that survivin could be widely applied as diagnostic markers and therapeutic targets in HNSCC patients. The prognostic value of survivin was investigated in HNSCC and gathering evidences suggested that survivin was an independent prognostic marker in HNSCC [46,47]. Epigenetic modifications play roles in HNSCC by regulating survivin expression [48]. The hypomethylation of BIRC5 is an important step in OSCC tumorigenesis due to its GC-rich region [49]. p53 also participates in the survivin upregulation in OSCCs, positive correlation was found between survivin expression and p53 in both HNSCC and premalignant lesions by Khan et al. [50]. The survivin gene locus encodes for multiple alternative splice variants with several different functions and heterodimerization possibilities [51]. Twenty three HNSCC cell lines at different differentiation levels showed higher survivin expressed levels compared to a human cell line of epidermal keratinocyte [52]. Targeted therapies have produced striking benefits for patients with cancers. Survivin is preferable targets of therapeutic modalities, namely antisense nucleotides, small-molecule inhibitors, antitumor immunotherapy and RNA interference [53,54]. According to our results, the survivin inhibitors could be the therapeutics against the HNSCC. The expression of survivin in HNSCC patients represents an important factor that predicts poor prognosis and resistance to chemo-and radiotherapy. The clinical application of survivin as a molecular target in HNSCC therapy significantly benefits HNSCC patients.
However, the present meta-analysis also had several limitations. First, we found that different paper qualities and sample sizes across the studies might cause bias in the meta-analysis. Second, the approaches used to evaluate the survivin expression were different, such as antibodies characters in IHC and instruments used in RT-PCR. Third, the cut-off value defining positive survivin expression varied among eligible studies (Table 1). Forth, our analysis might overestimate the prognostic significance of survivin to some degree due to the positive results reported in most of the including publications. Fifth, partial survival data of some including papers were extracted from Kaplan-Meier curves and may not as accurate as that obtained from original paper directly.
In conclusion, we searched the electronic databases and a total of 4891 patients in 28 studies were enrolled for meta-analysis, the results demonstrating that patients with survivin expression are more likely to have worse prognosis. Taken together, our meta-analysis results suggest that survivin gains a prognostic and diagnostic value for the HNSCC patients. However, more larger sample size studies are required to acquire a more representative and precise result.